Higher Rates Of Amputation And Ketoacidosis With Sglt2 Inhibitors: European Registry Data | Latest News RSS feed

Higher Rates Of Amputation And Ketoacidosis With Sglt2 Inhibitors: European Registry Data - Latest News


Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

(UPDATED) The use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is associated with more than a twofold increased risk of lower-limb amputations, as well as ... read more

SGLT2 Inhibitor Amputation Risk Seen in Real-World Diabetes Study

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, increasingly used in the treatment of type 2 diabetes, show as much as a twofold increase in the risks of lower limb amputations and diabetic ... read more

The SGLT2 Inhibitor-Amputation Link

As an example, the following article addresses the higher rate ... amputation. Why this happened is unclear and whether it occurs with all SGLT2 inhibitors is controversial. Concern about amputations ... read more

Looking for another news?


Diabetes and PAD investigated in revision rates of amputation

Overall, there was a 25.2 per cent revision rate ... revision amputation. "Considering the given data, a particular level of amputation cannot be recommended in patients with diabetes mellitus or PAD, ... read more


U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

CREDENCE is the first dedicated renal outcomes study of any sodium-glucose co-transporter 2 (SGLT2) inhibitor in patients with T2D and ... Stage 2 or 3 CKD (defined as an estimated glomerular ... read more

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Complications of the gangrene included diabetic ketoacidosis, sepsis/septic shock, and acute kidney injury. Eight patients required fecal diversion surgery and two needed amputations ... for SGLT2 ... read more

AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019

Data evaluating the cardiovascular (CV ... kind evaluating the risk of all-cause death and hHF in patients with T2D receiving treatment with a SGLT-2 inhibitor (SGLT-2i), including FARXIGA. Joris ... read more

Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes?

"These data suggest that SGLT2 inhibitors should ... which are usually easily managed and uncommonly recur." SGLT2 inhibitors do appear to increase the risk of diabetic ketoacidosis, but the rates ... read more

FDA: Diabetes Drug Invokana Can Cause Too Much Acid in Blood

This article was updated to include study data showing risk for type ... in a class of Type 2 diabetes drugs called SGLT2 inhibitors. According to the FDA’s warning, the drugs can cause a condition ... read more

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). Sotagliflozin (LX4211) is a new oral inhibitor of ... read more

Zackary Berger’s weekly research reviews—19 November

Perhaps because only chain pharmacies were contacted, or because telephone rather than in-person data were collected, the availability was higher ... SGLT2 inhibitors were lower limb amputations and ... read more

Lawsuits Filed Against J&J Related to its Drug Invokana

The European Medicines Agency (EMA) also has informed patients about potential increased risk of amputations for patients taking any SGLT2 inhibitors ... kidney failure, diabetic ketoacidosis, stroke, ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us